A Cancer Drug Under a Cloud
Several troubling but inconclusive studies suggest that EPO, a huge earner for Amgen and J&J, might actually lower survival rates
By Amy Tsao
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.